Olverembatinib for newly diagnosed Ph+ ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- You should be generally healthy enough to carry out daily activities (ECOG score 2 or lower).
- Your major organs (like liver and kidneys) must be working well enough.
- You must not have had a previous diagnosis of chronic myeloid leukemia (CML) or other cancers in the last 2 years.
- You cannot have serious heart problems, recent blood clots, or active infections needing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This study tests a new combination of two oral drugs (olverembatinib and APG-2575) for children with a type of leukemia (Ph+ ALL) that has returned or stopped responding to standard treatments. The goal is to see if this combination is safe and effective.
This trial tests a combination of two targeted drugs given before a stem cell transplant for people with a specific type of acute lymphoblastic leukemia (Ph+ ALL) that did not fully respond to initial treatment. The goal is to make the leukemia undetectable before transplant, which may improve outcomes.
This study tests a new targeted drug called olverembatinib for people with chronic myeloid leukemia (CML) that has stopped responding to other treatments. It aims to see if the drug can control the leukemia with fewer side effects.
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
Hear when a new Ph+ ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.